NCT06379867View on ClinicalTrials.gov

A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 7, 2024

Primary Completion Date

May 30, 2024

Study Completion Date

August 30, 2024

Conditions
Anesthesia
Interventions
DRUG

HSK3486

0.4 mg/kg, IV bolus administration

DRUG

Placebo

IV bolus administration

DRUG

Moxifloxacin

0.4 g, Oral administration with 240 mL

Trial Locations (1)

Unknown

RECRUITING

Beijing GoBroad Boren Hospital, Beijing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY